AURORA CANNABIS INC (ACB.CA) Stock Fundamental Analysis
Canada - TSX:ACB - CA05156X8504 - Common Stock
8.66 CAD
+1.89 (+27.92%)
We assign a fundamental rating of 3 out of 10 to ACB. ACB was compared to 34 industry peers in the Pharmaceuticals industry. The financial health of ACB is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ACB is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ACB had negative earnings in the past year.
ACB had a positive operating cash flow in the past year.
In the past 5 years ACB reported 4 times negative net income.
In the past 5 years ACB reported 4 times negative operating cash flow.
1.2 Ratios
ACB has a Return On Assets of -2.32%. This is comparable to the rest of the industry: ACB outperforms 52.94% of its industry peers.
ACB has a better Return On Equity (-3.53%) than 61.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.32% | ||
| ROE | -3.53% | ||
| ROIC | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 4.04%, ACB is doing worse than 76.47% of the companies in the same industry.
ACB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 4.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
2. Health
2.1 Basic Checks
ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACB has been increased compared to 1 year ago.
ACB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for ACB has been reduced compared to a year ago.
2.2 Solvency
ACB has an Altman-Z score of -9.18. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ACB (-9.18) is worse than 82.35% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that ACB is not too dependend on debt financing.
ACB's Debt to Equity ratio of 0.07 is fine compared to the rest of the industry. ACB outperforms 67.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.18 |
ROIC/WACCN/A
WACC9.18%
2.3 Liquidity
A Current Ratio of 2.97 indicates that ACB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.97, ACB is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
ACB has a Quick Ratio of 1.51. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
ACB has a better Quick ratio (1.51) than 64.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.97 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.79% over the past year.
The Revenue has grown by 28.42% in the past year. This is a very strong growth!
Measured over the past years, ACB shows a small growth in Revenue. The Revenue has been growing by 6.94% on average per year.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
Revenue 1Y (TTM)28.42%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%
3.2 Future
The Earnings Per Share is expected to grow by 103.58% on average over the next years. This is a very strong growth
Based on estimates for the next years, ACB will show a small growth in Revenue. The Revenue will grow by 7.42% on average per year.
EPS Next Y-288.53%
EPS Next 2Y206.48%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue Next Year8.72%
Revenue Next 2Y7.21%
Revenue Next 3Y6.04%
Revenue Next 5Y7.42%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
ACB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 18.44 indicates a rather expensive valuation of ACB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACB indicates a somewhat cheap valuation: ACB is cheaper than 79.41% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.18, ACB is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.44 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ACB's earnings are expected to grow with 81.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y206.48%
EPS Next 3Y81.3%
5. Dividend
5.1 Amount
No dividends for ACB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:ACB (9/29/2025, 7:00:00 PM)
8.66
+1.89 (+27.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners15.09%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap487.13M
Analysts73.33
Price Target8.08 (-6.7%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-321.48%
Min EPS beat(2)-426.74%
Max EPS beat(2)-216.23%
EPS beat(4)1
Avg EPS beat(4)935.07%
Min EPS beat(4)-426.74%
Max EPS beat(4)4494.06%
EPS beat(8)3
Avg EPS beat(8)450.07%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)0.93%
Revenue beat(4)3
Avg Revenue beat(4)7.13%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)14.66%
Revenue beat(8)6
Avg Revenue beat(8)3.86%
Revenue beat(12)7
Avg Revenue beat(12)2.68%
Revenue beat(16)9
Avg Revenue beat(16)2.74%
PT rev (1m)0%
PT rev (3m)-16.05%
EPS NQ rev (1m)55.57%
EPS NQ rev (3m)55.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-127.78%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)10.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.44 | ||
| P/S | 1.36 | ||
| P/FCF | N/A | ||
| P/OCF | 26.12 | ||
| P/B | 0.88 | ||
| P/tB | 1.06 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.35
EYN/A
EPS(NY)0.47
Fwd EY5.42%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.33
OCFY3.83%
SpS6.36
BVpS9.81
TBVpS8.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.32% | ||
| ROE | -3.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 4.04% | ||
| FCFM | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 81.56% | ||
| Cap/Sales | 5.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.97 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z | -9.18 |
F-Score6
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
EPS Next Y-288.53%
EPS Next 2Y206.48%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue 1Y (TTM)28.42%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%
Revenue Next Year8.72%
Revenue Next 2Y7.21%
Revenue Next 3Y6.04%
Revenue Next 5Y7.42%
EBIT growth 1Y4.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.45%
EBIT Next 3Y29.76%
EBIT Next 5Y25.22%
FCF growth 1Y92.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y208.3%
OCF growth 3YN/A
OCF growth 5YN/A